The Effect of Shexiang Baoxin Pill on Microvascular Function and Levels of PECAM-1 and CD62P in Patients with Stable Angina Pectoris of Coronary Heart Disease
Objective To investigate the adjuvant therapeutic effect of Shexiang Baoxin pill in patients with stable angina pectoris(SA)of coronary heart disease,and to analyze its effects on microvascular function,platelet-endothelial cell adhesion molecule(PECAM-1)and P-selectin(CD62P)levels.Methods 120 patients with SA admitted to our hospital from February 2021 to February 2023 were selected as research objects,and they were divided into a routine group and a Baoxin pill group according to random number table method,with 60 cases in each group.The conventional group was treated with conventional drugs,while the Baoxin pill group was treated with musk Baoxin pill.The clinical effect,angina pectoris attack,microvascular function,inflammatory chemokines and platelet activation function were observed.Results The total effective rate of Baoxin pill group was 93.33％,which was higher than 80.00％ of conventional group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the frequency and duration of angina pectoris between the two groups(P>0.05);after 3 months of treatment,the frequency of angina pectoris in Baoxin pill group was lower than that in conventional group,and the duration of angina pectoris was shorter than that in control group,the differences were statistically significant(P<0.05).After 3 months of treatment,the frequency of angina pectoris in Baoxin pill group was(2.53±0.68)times/week less than(4.07±1.02)times/week in conventional group,and the duration of angina pectoris in Baoxin pill group was(1.28±0.18)min/time shorter than(2.64±0.47)min/time in conventional group,the differences between groups were statistically significant(P<0.05).Before treatment,there were no significant differences in microcirculation resistance index(IMR)and coronary flow reserve(CFR)between the two groups(P>0.05);after 3 months of treatment,the IMR(17.65±1.32)U in Baoxin-pill group was lower than(21.47±1.46)U in conventional group,and the CFR(2.37±0.25)was higher than(1.84±0.32)in conventional group,with statistical significance(P<0.05).Before treatment,there were no significant Metallomatrix Proteinase-9(MMP-9),soluble Intercellular Adhesion Molecule(sICAM-1),tissue Plasminogen Activator Inhibitor TypeⅠ(tPAI-Ⅰ)between the two groups(P>0.05);after 3 months of treatment,the levels of MMP-9 of(17.25±3.12)μg/L,sICAM-1(213.37±54.15)ng/mL and PAI-1(4.31±0.57)kU/L in Baoxin pill group were lower than(23.46±4.07)μg/L,(239.65±61.78)ng/mL,(6.45±0.69)kU/L in conventional group,the differences between groups were statistically significant(P<0.05).Before treatment,there were no significant differences in PECAM-1 and CD62P between the two groups(P>0.05);after 3 months of treatment,PECAM-1(68.82±1.37)％and CD62P(4.68±1.03)％ in Baoxin pill group were lower than(72.37±1.26)％ and(5.37±1.14)％in conventional group,and the differences were statistically significant(P<0.05).Conclusion Shexiang Baoxin pill has a good therapeutic effect in SA patients,which can enhance the inhibition of the expression of inflammatory chemokines in the body,effectively alleviate the platelet activation reaction produced by PECAM-1 and CD62P in the body,improve the microvascular function,reduce the number of angina pectoris attacks and shorten the duration of attacks.
Stable angina pectoris of coronary heart diseaseShexiang Baoxin pillMicrovascular functionPlatelet activation function
NETL
NSTL
万方数据
